Virax Biolabs Group Limited Ordinary Shares (VRAX) - Net Assets
Based on the latest financial reports, Virax Biolabs Group Limited Ordinary Shares (VRAX) has net assets worth $5.07 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.72 Million) and total liabilities ($641.52K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Virax Biolabs Group Limited Ordinary Sha liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $5.07 Million |
| % of Total Assets | 88.77% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 24.29 |
Virax Biolabs Group Limited Ordinary Shares - Net Assets Trend (2020–2025)
This chart illustrates how Virax Biolabs Group Limited Ordinary Shares's net assets have evolved over time, based on quarterly financial data. Also explore how large is Virax Biolabs Group Limited Ordinary Sha's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Virax Biolabs Group Limited Ordinary Shares (2020–2025)
The table below shows the annual net assets of Virax Biolabs Group Limited Ordinary Shares from 2020 to 2025. For live valuation and market cap data, see Virax Biolabs Group Limited Ordinary Sha market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | $5.46 Million | +6.29% |
| 2024-03-31 | $5.14 Million | -42.29% |
| 2023-03-31 | $8.90 Million | +844.04% |
| 2022-03-31 | $-1.20 Million | -53.95% |
| 2021-03-31 | $-777.32K | +36.03% |
| 2020-03-31 | $-1.22 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Virax Biolabs Group Limited Ordinary Shares's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2061208900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.34K | 0.08% |
| Other Comprehensive Income | $30.28 Million | 531.61% |
| Total Equity | $5.70 Million | 100.00% |
Virax Biolabs Group Limited Ordinary Shares Competitors by Market Cap
The table below lists competitors of Virax Biolabs Group Limited Ordinary Shares ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CREATIVEF. G.S.A-K ZY-23
F:19F
|
$981.46K |
|
Mulberry Group PLC
LSE:MUL
|
$981.70K |
|
22nd Century Group Inc
NASDAQ:XXII
|
$988.23K |
|
TH1NG AB
ST:TH1NG
|
$988.27K |
|
Companhia Tecidos Santanense Ltda
SA:CTSA3
|
$979.70K |
|
FKS Food Sejahtera Tbk PT
JK:AISA
|
$972.99K |
|
HCW Biologics Inc
NASDAQ:HCWB
|
$972.53K |
|
Iofina plc
LSE:IOF
|
$968.76K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Virax Biolabs Group Limited Ordinary Shares's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,366,757 to 5,696,120, a change of 329,363 (6.1%).
- Net loss of 6,061,247 reduced equity.
- New share issuances of 5,128,186 increased equity.
- Other comprehensive income increased equity by 6,388,842.
- Other factors decreased equity by 5,126,418.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-6.06 Million | -106.41% |
| Share Issuances | $5.13 Million | +90.03% |
| Other Comprehensive Income | $6.39 Million | +112.16% |
| Other Changes | $-5.13 Million | -90.0% |
| Total Change | $- | 6.14% |
Book Value vs Market Value Analysis
This analysis compares Virax Biolabs Group Limited Ordinary Shares's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.07x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-03-31 | $-0.93 | $0.13 | x |
| 2021-03-31 | $-0.52 | $0.13 | x |
| 2022-03-31 | $-0.86 | $0.13 | x |
| 2023-03-31 | $8.59 | $0.13 | x |
| 2024-03-31 | $2.67 | $0.13 | x |
| 2025-03-31 | $1.84 | $0.13 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Virax Biolabs Group Limited Ordinary Shares utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -106.41%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -95739.17%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.13x
- Recent ROE (-106.41%) is below the historical average (-48.61%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | -802.13% | 4.42x | 0.00x | $-695.52K |
| 2021 | 0.00% | -525.75% | 1.32x | 0.00x | $-591.37K |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.61 Million |
| 2023 | -59.80% | -63748.32% | 0.00x | 1.08x | $-6.37 Million |
| 2024 | -125.47% | -4304.81% | 0.03x | 1.02x | $-7.27 Million |
| 2025 | -106.41% | -95739.17% | 0.00x | 1.13x | $-6.63 Million |
Industry Comparison
This section compares Virax Biolabs Group Limited Ordinary Shares's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Virax Biolabs Group Limited Ordinary Shares (VRAX) | $5.07 Million | 0.00% | 0.13x | $979.89K |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Virax Biolabs Group Limited Ordinary Shares
Virax Biolabs Group Limited, a biotechnology company, distributes diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of T cell in Vitro Diagnostics. The company offers various in-vitro diagnostics test kits comprising respiratory, pregnancy and fertility, infectious diseases, sti, drugs of abuse, oncology, cardiac, women's health, ot… Read more